Compare BRAI & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRAI | FTH |
|---|---|---|
| Founded | 2022 | 1999 |
| Country | Australia | United States |
| Employees | 800 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.5M | 835.7M |
| IPO Year | N/A | 2021 |
| Metric | BRAI | FTH |
|---|---|---|
| Price | $4.58 | $23.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $56.67 |
| AVG Volume (30 Days) | 22.0K | ★ 393.8K |
| Earning Date | 11-14-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.22 | $17.50 |
| 52 Week High | $32.32 | $42.14 |
| Indicator | BRAI | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 30.01 |
| Support Level | N/A | N/A |
| Resistance Level | $5.87 | $31.37 |
| Average True Range (ATR) | 0.41 | 2.38 |
| MACD | -0.08 | -0.65 |
| Stochastic Oscillator | 29.13 | 0.64 |
Braiin Ltd is an Australian technology company leveraging proprietary intellectual property and patented artificial intelligence/machine learning (AI/ML) technologies to deliver actionable insights across the verticals: Agriculture, Property Technology, and Customer Experience as a Service (CXaaS). The company's platforms are designed to address inefficiencies and drive data-backed decision-making across traditionally analog sectors. It prominently focuses on the agriculture technology sector, where it has successfully deployed its AI-powered solutions across multiple implementations. It provides end-to-end solutions to improve farming productivity using IoTs, Wireless Connectivity, Robotics, Software and AI/ML.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.